Francis, Kate L
McKinlay, Christopher J D
Kamlin, C Omar F
Cheong, Jeanie L Y
Dargaville, Peter A
Dawson, Jennifer A
Doyle, Lex W
Jacobs, Susan E
Davis, Peter G
Donath, Susan M
Manley, Brett J http://orcid.org/0000-0003-0212-7956
Funding for this research was provided by:
National Health and Medical Research Council (1158555)
Chiesi Farmaceutici
Article History
Received: 14 August 2023
Accepted: 12 September 2023
First Online: 6 November 2023
Declarations
:
: The PLUSS trial has been approved by the following human research ethics committees:1. The Royal Children’s Hospital, Melbourne, Australia: Reference 36383.2. Mercy Health Human Research Ethics Committee, Melbourne, Australia: Reference 2019–017.3. Mater Misericordiae Ltd Human Research Ethics Committee, Brisbane, Australia: Reference 55212.4. Central Health and Disability Ethics Committee, New Zealand: Reference 17/CEN/203.5. SINGHEALTH Centralised Institutional Review Board (CIRB), Singapore: Reference 2019/2801.6. University of Alberta Research Ethics Office, Canada: Reference Pro00083572.
: Not applicable.
: The authors declare that they have no competing interests.